Sipuleucel-T (Provenge®)—Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention
Crossref DOI link: https://doi.org/10.1007/s40259-015-0140-7
Published Online: 2015-09-24
Published Print: 2015-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jarosławski, Szymon
Toumi, Mondher
Text and Data Mining valid from 2015-09-24